Technical report

Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease

EuroIntervention 2011;7:274-277 published online ahead of print May 2011. DOI: 10.4244/EIJV7I2A44

Juan-Luis Gutiérrez-Chico
Juan Luis Gutierrez-Chico, MD, PhD; Evelyn Regar, MD, PhD; Robert-Jan van Geuns, MD, PhD; Scot Garg, MD, PhD; Carl Schultz, MD, PhD; Nicolas van Mieghem, MD; Henricus Duckers, MD, PhD; Patrick W Serruys*, MD, PhD, FESC
Interventional Cardiology Department, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands

The Moxy drug-coated PTCA/PTA balloon (Lutonix, Inc. Maple Grove, MN, USA) is a paclitaxel-coated balloon with a hydrophilic carrier to optimize the drug release onto the vessel wall. It represents an interesting alternative to drug-eluting stent (DES) for the percutaneous treatment of in-stent restenosis, de novo coronary lesions or peripheral artery disease.


Adoption of DES has reduced coronary restenosis rates to 7.9-8.9% at nine months1-3, but this benefit is compromised by a higher incidence of late and very late stent thrombosis4-8. The polymer component of DES may contribute to inflammation of the ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
How should I treat a huge intra-mural haematoma of the ascending aorta after coronary angioplasty?

Latest news